Almirall and etherna partner to develop mRNA-based therapies for severe skin diseases

2023-12-13

引进/卖出信使RNA蛋白降解靶向嵌合体

Almirall and etherna partner to develop mRNA-based therapies for severe skin diseases

Preview

来源: PMLiVE

Almirall has announced a new multi-target alliance with etherna to discover and develop new mRNA-based therapies to treat dermatological diseases.

The alliance will combine mRNA and lipid nanoparticle (LNP) technology to accelerate the discovery of new treatments for severe skin diseases, including non-melanoma skin cancer.

Estimated to affect 1.8 billion people worldwide, dermatological diseases consist of conditions that irritate, clog or damage the skin.

The companies will utilise etherna's proprietary mRNA capabilities and LNP formulations with Almirall's expertise in medical dermatology.

Both will work together on research activities, while Almirall will be responsible for leading clinical development and commercialisation.

The mRNA/LNP technology platform company’s delivery of LNP-formulated mRNA for transient and local translation of therapeutic proteins works to encode multiple therapeutically active components within a single treatment.

Under the terms of the agreement, etherna will receive an upfront and technology access payment from Almirall, as well as up to €300m in success-based development and commercial milestone payments contingent upon the launch and commercial success of several products.

In addition to this, etherna will also be eligible to receive tiered royalties based upon future global sales.

Dr Karl Ziegelbauer, chief scientific officer of Almirall, said: “At Almirall, we always look for new solutions for patients suffering from skin diseases and we are thrilled about the strategic alliance with etherna to strengthen our pipeline with mRNA-based assets.”

Bernard Sagaert, chief executive officer of etherna, commented: “Intradermal application of LNP-formulated mRNA is a highly promising strategy to bring novel, efficacious new treatment options that will deliver huge benefits to patients.”

In November, Almirall announced a drug discovery partnership with Absci worth over $650m, utilising Absci’s Integrated Drug Creation platform to develop and commercialise artificial intelligence (AI)-designed treatments for dermatological diseases.

Earlier this month, Almirall announced a new partnership with the Barcelona Supercomputing Center-Centro Nacional de Supercomputatión and Nostrum Biodiscovery to find new therapies to treat dermatological diseases.

For the next three years, the ARTIBAND collaboration will explore AI and machine learning tools to design new protein-protein modulators for new therapies to treat several skin conditions.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构